CombiGene featured in an article in Nature, one of the world’s leading scientific journals
August 29 2018 Biostock Live
Jan Nilsson tell us about the future among other things in an interview with Finwire
R&D manager Karin Agerman and CEO Jan Nilsson are interviewed in conjunction with BioStock Live Capital Market Day
“Apparently FDA have a lot of fate in the possibilities of gene-therapy” Interview with Jan Nilsson
Kapitalmarknadsdag in Stockholm with several leading life science companies in which CombiGene also participated (In swedish)
Onsdagen 29 augusti arrangerade Biostock en kapitalmarknadsdag i Stockholm med flera ledande life science-bolag där också CombiGene deltog med VD Jan Nilsson och FoU chefen Karin Agerman. CombiGene AB, Medicon Village, SE-223-81 Lund. Besöksadress:...
read moreAbout CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.
Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden